ATRC (AtriCure) Cyclically Adjusted Revenue per Share: $8.38 (As of Mar. 2026)


ATRC AtriCure Inc ATRC
76 GF Score
Price $31.80
GF Value $39.83
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AtriCure Cyclically Adjusted Revenue per Share?

AtriCure ATRC +6.97% 76 Cyclically Adjusted Revenue per Share is $8.38 as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.83 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AtriCure's adjusted revenue per share for the three months ended in Mar. 2026 was $2.880. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.38 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AtriCure's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AtriCure was 9.30% per year. The lowest was -7.80% per year. And the median was 5.40% per year.

As of today (2026-07-05), AtriCure's current stock price is $31.80. AtriCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $8.38. AtriCure's Cyclically Adjusted PS Ratio of today is 3.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AtriCure was 15.67. The lowest was 2.93. And the median was 5.70.


AtriCure  (NAS:ATRC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AtriCure's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31.80/8.38
=3.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AtriCure was 15.67. The lowest was 2.93. And the median was 5.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AtriCure Cyclically Adjusted Revenue per Share Related Terms


AtriCure Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AtriCure's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure Cyclically Adjusted Revenue per Share Chart

AtriCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.68 6.21 6.76 7.40 8.10

AtriCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.61 7.80 7.98 8.10 8.38

ATRC vs KMTS, STAA, BLFS: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AtriCure's Cyclically Adjusted PS Ratio falls into.


ATRC
76GF Score
AtriCure Inc ATRC
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtriCure Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AtriCure's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.88/330.2130*330.2130
=2.880

Current CPI (Mar. 2026) = 330.2130.

AtriCure Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.256 241.018 1.721
201609 1.209 241.428 1.654
201612 1.294 241.432 1.770
201703 1.289 243.801 1.746
201706 1.401 244.955 1.889
201709 1.294 246.819 1.731
201712 1.410 246.524 1.889
201803 1.427 249.554 1.888
201806 1.558 251.989 2.042
201809 1.486 252.439 1.944
201812 1.449 251.233 1.905
201903 1.459 254.202 1.895
201906 1.578 256.143 2.034
201909 1.496 256.759 1.924
201912 1.605 256.974 2.062
202003 1.376 258.115 1.760
202006 0.980 257.797 1.255
202009 1.244 260.280 1.578
202012 1.307 260.474 1.657
202103 1.328 264.877 1.656
202106 1.585 271.696 1.926
202109 1.528 274.310 1.839
202112 1.586 278.802 1.878
202203 1.638 287.504 1.881
202206 1.850 296.311 2.062
202209 1.817 296.808 2.021
202212 1.917 296.797 2.133
202303 2.028 301.836 2.219
202306 2.181 305.109 2.360
202309 2.118 307.789 2.272
202312 2.294 306.746 2.469
202403 2.330 312.332 2.463
202406 2.479 314.175 2.606
202409 2.461 315.301 2.577
202412 2.637 315.605 2.759
202503 2.608 319.799 2.693
202506 2.853 322.561 2.921
202509 2.802 324.800 2.849
202512 2.930 324.054 2.986
202603 2.880 330.213 2.880

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $8.38 mean?
AtriCure (ATRC) has a Cyclically Adjusted Revenue per Share of $8.38 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AtriCure and its competitors.
Is AtriCure's Cyclically Adjusted Revenue per Share too high?
AtriCure's current Cyclically Adjusted Revenue per Share is $8.38. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Cyclically Adjusted Revenue per Share compare to KMTS and STAA?
AtriCure's Cyclically Adjusted Revenue per Share of $8.38 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AtriCure and its competitors. AtriCure's current Cyclically Adjusted Revenue per Share is $8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.83, compared to a current price of $31.80 — trading 20.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $8.38. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AtriCure (ATRC), the current Cyclically Adjusted Revenue per Share is $8.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be undervalued. The current stock price of $31.80 is trading 20.2% below its estimated GF Value™ of $39.83. GuruFocus considers AtriCure to be Modestly Undervalued.

Key valuation signals for ATRC:

  • Cyclically Adjusted Revenue per Share: $8.38
  • GF Value™: $39.83 vs. price of $31.80 (20.2% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AtriCure Business Description

Address 7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score

Get the complete analysis for ATRC

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.80
Price
$39.83
GF Value